Sugi Predict

Sugi Predict / Compounds / SCHEMBL6735517

SCHEMBL6735517

SCHEMBL6735517

CS(=O)(=O)c1c(F)cc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(Cl)c(Cl)c2)cc1F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.39
▸ ESR2 Q92731 1/20 0.39
▸ BRAF P15056 4/20 0.39
▸ CASP1 P29466 1/20 0.38
▸ PTGS1 P23219 6/20 0.36
▸ PTGS2 P35354 6/20 0.36
▸ LMNA P02545 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ MAPK13 O15264 1/20 0.34
▸ RAF1 P04049 1/20 0.34
▸ MAPK12 P53778 1/20 0.34
▸ MAPK11 Q15759 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ GLP1R P43220 1/20 0.34
▸ KIF11 P52732 1/20 0.34
▸ NOTUM Q6P988 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ SCN9A Q15858 1/20 0.33
▸ TGFBR1 P36897 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6734647 0.91 PTGS2 (0.42) ESR1ESR2BRAFCASP1PTGS1
SCHEMBL6734278 0.91 PTGS2 (0.42) ESR1ESR2BRAFCASP1PTGS1
SCHEMBL6735038 0.89 PTGS1 (0.47) ESR1ESR2BRAFCASP1PTGS1
SCHEMBL6734050 0.89 PTGS2 (0.44) ESR1ESR2BRAFCASP1PTGS1
SCHEMBL6736178 0.89 PTGS2 (0.45) ESR1ESR2PTGS1PTGS2LMNA
SCHEMBL6729665 0.89 ESR1 (0.42) ESR1ESR2BRAFCASP1PTGS1
SCHEMBL6718671 0.88 BRAF (0.43) ESR1ESR2BRAFPTGS1PTGS2
SCHEMBL6739990 0.86 CASP1 (0.41) ESR1ESR2BRAFCASP1PTGS1
SCHEMBL6728463 0.86 PTGS2 (0.49) ESR1ESR2BRAFPTGS1PTGS2
SCHEMBL6735783 0.86 ESR1 (0.41) ESR1ESR2BRAFCASP1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 — — US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 — — US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 — — US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 — — US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 — — US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 ESR1 1259/4885ESR2 201/4885BRAF 763/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 ESR1 1259/4885ESR2 201/4885BRAF 763/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 ESR1 1259/4885ESR2 201/4885BRAF 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.